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SOX9 regulated matrix proteins 
are increased in patients serum 
and correlate with severity of liver 
fibrosis
Varinder S. Athwal  1,2,3, James Pritchett  1,2,4, Katherine Martin1,2,3, Jessica Llewellyn2, 
Jennifer Scott1,2,3, Emma Harvey2, Abed M. Zaitoun5, Aoibheann F. Mullan1,2,3, Leo A. H. Zeef6, 
Scott L. Friedman  7, William L. Irving8,9, Neil A. Hanley2,3, Indra N. Guha  8 & 
Karen Piper Hanley1,2,3
Extracellular matrix (ECM) deposition and resultant scar play a major role in the pathogenesis and 
progression of liver fibrosis. Identifying core regulators of ECM deposition may lead to urgently needed 
diagnostic and therapetic strategies for the disease. The transcription factor Sex determining region 
Y box 9 (SOX9) is actively involved in scar formation and its prevalence in patients with liver fibrosis 
predicts progression. In this study, transcriptomic approaches of Sox9-abrogated myofibroblasts 
identified >30% of genes regulated by SOX9 relate to the ECM. Further scrutiny of these data identified 
a panel of highly expressed ECM proteins, including Osteopontin (OPN), Osteoactivin (GPNMB), 
Fibronectin (FN1), Osteonectin (SPARC) and Vimentin (VIM) as SOX9 targets amenable to assay in 
patient serum. In vivo all SOX-regulated targets were increased in human disease and mouse models 
of fibrosis and decreased following Sox9-loss in mice with parenchymal and biliary fibrosis. In patient 
serum samples, SOX9-regulated ECM proteins were altered in response to fibrosis severity, whereas 
comparison with established clinical biomarkers demonstrated superiority for OPN and VIM at detecting 
early stages of fibrosis. These data support SOX9 in the mechanisms underlying fibrosis and highlight 
SOX9 and its downstream targets as new measures to stratify patients with liver fibrosis.
Liver fibrosis is increasing and a major cause of morbidity and mortality1–3. It is a feature of most chronic liver 
diseases and is characterized by progressive deposition of extracellular matrix (ECM) proteins resulting in patho-
logical scaring and tissue dysfunction4. Although potentially reversible during early stages, a significant number 
of patients progress to advanced fibrosis and end-stage cirrhosis, increasing the risk of hepatocellular carcinoma 
(HCC)5–7. Identifying the extent of fibrosis and risk of progression would provide a valuable clinical tool.
Liver biopsy remains an important measure to assess fibrosis. However, several biological tests already in 
clinical use have taken advantage of secreted factors associated with the pathogenesis of liver fibrosis including 
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ECM remodeling (Tissue inhibitor of metalloproteinases-1; TIMP1) and deposition (Procollagen III propep-
tide; PIIIP)8–11. Consequently core regulators of ECM deposition could be exploited to identify useful targets for 
urgently needed diagnostic and therapetic strategies for the disease. We have previously identified the transcrip-
tion factor, Sex determining region Y box 9 (SOX9), as a key factor regulating multiple components of the fibrotic 
ECM in liver disease whereas its prevalence in patient biopsy samples predicts progression towards cirrhosis12–16.
These studies stem from SOX9’s critical role in bone development and its requirement in chondrogenesis, 
whereby the initial cartilaginous skeletal elements are formed and serve as a template for endochondral bone 
formation14,17,18. Here SOX9 transcriptionally activates many cartilage-specific ECM genes such as Collagens 
type-2, 9, 11 and 27, Aggrecan, Matrillin-1 and Cartilage Oligomeric Protein14,17–19. Importantly, SOX9 is silenced 
in terminally differentiated chondrocytes prior to ossification17. This context-specific expression of SOX9 is medi-
ated by several signaling pathway, many of which become dysregulated in fibrotic disease4,14. In light of this and 
in response to profibrotic signaling factors, SOX9 becomes expressed by the fibrogenic cell-type, the activated 
hepatic stellate cell (HSC), a myofibroblast that contains α-smooth muscle actin (αSMA) and regulates the pro-
duction of ECM components, type 1 Collagen (COL1) and OPN13,15,16, both implicated in disease progression20,21, 
and inhibits the collagenase Matrix metalloproteinase-13 (MMP13)15. In the context of fibrosis and increased 
organ stiffness, studies in development, liver fibrosis and regeneration all support mechanisms involving the 
mechanosenstive factor Yes associated protein-1 (YAP-1) as important in the regulation of SOX922–24. In vivo, 
mice lacking SOX9 have significantly reduced scarring, improved liver function and less inflammation in models 
of fibrosis12. Data from multiple transgenic models to inactivate SOX9 support hepatic myofibroblasts as the caus-
ative cell-type mediating fibrosis12. In human patients with chronic liver disease, the profile and localization of 
SOX9 was identical to rodent suggesting the mechanisms underlying SOX9 function in fibrosis are likely to be the 
same12. Moreover, the extent of SOX9 in biopsies from patients with chronic liver disease correlated with fibrosis 
severity and accurately predicted disease progression towards cirrhosis12.
As an extension to these data placing SOX9 in the mechanism underlying fibrosis, we hypothesized that 
defining downstream SOX9 targets in liver myofibroblasts would identify ECM components amenable to 
assay in serum from patients with chronic liver disease. Through transcriptomic and experimental analysis of 
Sox9-abrogated and wild-type liver myofibroblasts, gene ontology and functional analysis identified >30% of 
genes regulated by SOX9 relate to the ECM. Further scrutiny of these data identified a panel of highly expressed 
ECM proteins, verified in vitro and in vivo as SOX9 targets that correlated with severity of fibrosis in patient 
serum samples.
Results
SOX9 regulates multiple ECM proteins in HSCs. Transcriptome analysis of Sox9 depleted activated rat 
HSCs (ArHSCs) compared to control cells resulted in a total of 540 differentially regulated genes (± ≥ 1.2 fold, 
p < 0.05; Supplementary Figure 1A-B, Supplementary Information File 1 and microarray dataset E-MTAB-7298). 
Verification of the top 15 SOX9-regulated genes indicated 87% of positive targets were in line with our microarray 
data (Supplementary Fig. 1C,D). Gene ontology and functional annotation analysis revealed 37% of genes regu-
lated by SOX9 related to the ECM (Fig. 1 and Supplementary Figs 2 and 3). Combined with our previous data and 
its ability to transcriptionally activate a repertoire of ECM genes during chondrogenesis13,15,16,25, these data sup-
port SOX9’s central role in fibrotic mechanisms resulting in scar formation and subsequent tissue destruction12.
Further scrutiny of this dataset discovered a cohort of highly expressed genes, with transcript levels above 
the threshold levels for the microarray platform to perform an assay. Significantly, this group contained known 
SOX9 regulated genes, Opn (or Spp1) and Col113,16. As a result, we were interested to determine whether other 
matrix proteins were similarly regulated by SOX9 in these data. From 169 highly expressed genes (with ≥3800 
arbitrary units of expression), 41% of transcripts encoded ribosomal proteins; further highlighting the abundant 
levels of the remaining genes in activated HSCs (Supplementary Table 3). Following ribosomal gene removal, 
from the remaining 100 transcripts (Supplementary Table 3) we identified a subgroup of 24 genes encoding 
functional proteins emphasizing the phenotype of activated HSCs (Table 1). This list contained genes relevant 
to pro-inflammatory ligands and contractile cytoskeletal factors (Table 1). However, 10 genes encoded secreted 
matrix proteins potentially amenable to assay in patient serum samples (asterisks; Table 1).
Figure 1. SOX9 regulates multiple ECM proteins in HSCs. (A) Function annotation for gene ontology of all 
Sox9-regulated genes (±1.2 fold, p < 0.05) represented as proportion of individual categories outlined and listed 
in Supplementary Figure 2. (B) Top 5 canonical pathways represented and Sox9-regulated genes listed. Down-
regulated genes (purple) and up-regulated (red) are highlighted following Sox9-loss.
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To evaluate if the identified factors were regulated by SOX9, we abrogated SOX9 expression in activated HSCs 
using siRNA (Fig. 2A). A reduction in mRNA and protein levels of 5 SOX9 targets, namely Opn, Gpnmb, Fn1, 
Sparc, and Vim was uncovered (Fig. 2B–D). Compared to quiescent HSC controls, transcript and protein lev-
els were increased in activated HSCs (Fig. 2E–G). Eno1 (Enolase) expression was significantly reduced by Sox9 
knockdown (Fig. 2A), but did not show any change in activated HSCs compared to quiescent controls (data not 
shown) and hence not pursued. Immunocytochemistry showed presence of all five factors in activated rat and 
human HSCs (Fig. 3A).
Similar to our previous work on Opn16, in-silico analysis identified conserved SOX9 binding motifs in Gpnmb, 
Fn1, Sparc and Vim within regions <3Kb upstream of the transcriptional start site (Supplementary Figure 4). 
Consistent with this16, Opn, Gpnmb, Fn1 and Sparc enrichment was demonstrated in activated rHSCs following 
ChIP with a SOX9 antibody (Fig. 3B), whereas Vim did not appear to be directly regulated by SOX9 through this 
binding site.
SOX9-targets detected in fibrotic areas in mouse and human and reduced following 
Sox9-loss. We have previously described improved fibrosis in Sox9-null mice12. In line with this, expres-
sion of all targets were increased following fibrosis induction by CCl4 and BDL in control mice (Sox9fl/fl; 
RosaCreER−/−), whereas all were reduced following Sox9-loss (Sox9fl/fl; RosaCreER+/−) (Figs 4 and 5 
and Supplementary Figs 5 and 6). Similar to mouse, liver biopsy samples from patients with advanced fibro-
sis secondary to chronic hepatitis C (CHC) showed high levels of all identified SOX9 targets in advanced 
fibrosis/cirrhosis (IS6; Fig. 6 and Supplementary Fig. 7). In line with our previous work and rodent models 
of fibrosis (Supplementary Figs 8 and 9), the patient samples expressed increased levels of SOX9 and α-SMA 
(Supplementary Fig. 7)12.
Analysis of the SOX9 ECM panel as markers of liver fibrosis. These data suggested the SOX9 down-
stream targets, OPN, VIM, SPARC, GPNMB and FN1, were secreted from activated HSCs and increased in 
fibrotic disease. To ascertain clinical significance, we investigated whether SOX9 regulated proteins could be 
used to assess fibrosis in serum samples from a well phenotyped, experimental cohort of patients with CHC (and 
non-infected controls). This cohort consisted of 50 patients with parallel serum and liver biopsy samples. Fibrosis 
was assessed by biopsies and staged using the Metavir system. Breakdown by fibrosis stage was: controls (n = 11), 
F0 (n = 6), F1 (n = 12), F2 (n = 9), F3 (n = 1) and F4/cirrhosis (n = 11). With only a single sample from a patient 
with F3 fibrosis, this was amalgamated into F4 as representative analysis of clinically advanced fibrosis.
Concentration of individual proteins was assayed in the serum samples using ELISA based immunoassay. 
Assay consistency and accuracy was assessed using the average coefficient of variation (CoV). For each protein 
assayed, CoV was: OPN – 6.66%, VIM – 4.74%, SPARC 4.60%, GPNMB 6.01% and FN1–8.20%. A CoV below 
10% is laboratory standard for accuracy and all ELISAs fulfilled this criterion. Serum concentrations from three of 
Gene Symbol Gene Title
Vim* vimentin
Gpnmb* glycoprotein transmembrane nmb (osteoactivin)
Spp1* secreted phosphoprotein 1 (osteopontin)
Ctgf* connective tissue growth factor
Ccl2 chemokine (C-C motif) ligand 2
Pf4 platelet factor 4/chemokine (C-X-C motif) ligand 4
Txn1 thioredoxin 1
Ccl7 chemokine (C-C motif) ligand 7
Tpm2 tropomyosin 2
Ctsl1 cathepsin L1
Ctsb cathepsin B
Mgp* matrix Gla protein
Tagin* Transgelin
Cxcl3 chemokine (C-X-C motif) ligand 3
Sparc* secreted protein, acidic, cysteine-rich (osteonectin)
Cd63 Cd63 molecule
Cox2 cyclo-oxygenase 2
Cxcl3 chemokine (C-X-C motif) ligand 3
Eno1 enolase 1, (alpha Enolase)
Timp1* Tissue metallopeptidase inhibitor 1
Cryab crystallin, alpha B
Col1a2* collagen, type I, alpha 2
Tpm4 tropomyosin 4
Fn1* fibronectin 1
Table 1. Subgroup of highly expressed HSC transcripts encoding secreted proteins.
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Figure 2. Identification of a panel of Sox9-regulated genes in HSCs. (A) Comparative levels and representation 
of highly expressed factors after knockdown of Sox9 in activated rat HSCs (*in A signifies statistically significant 
change). Relative mRNA levels by qRT-PCR analysis and protein levels quantified by immunoblotting in rHSCs 
following Sox9 abrogation using siRNA (B) and (C), representative immunoblot shown in (D) or quiescent and 
activated rHSCs (E) and (F, representative immunoblot shown in (G). All experiments are n ≥3. Data are shown 
as means ± s.e.m. *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 3. SOX9 is localized and directly binds to its ECM targets in HSCs. (A) Immunofluorescence in 
activated HSCs from rat (rHSCs; top panel) and human (hHSCs; bottom panel). Nuclear SOX9 shown in 
red with OPN, GPNMB, SPARC, VIM and FN1 shown in green. Co-localisation is shown where antibody 
compatibility allows. DAPI nuclear stain (blue). Scale bar 10 μm. (B) ChIP assay for SOX9 binding element in 
primary rat HSCs with negative controls (IgG and ChIP negative primers) and positive control (Input diluted 
1:10). n = 3. SOX9 enrichment (IP) is shown for Fn1, Gpnmb, Sparc and Spp1 (Opn).
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the five tested proteins had promising performance to predict fibrosis stage (Fig. 7). Concentrations of OPN, VIM 
and SPARC increased in a step-wise manner, although VIM concentrations did not alter significantly between lat-
ter fibrosis stages F2–4 (Fig. 7). Similar results were observed in a second HCV cohort, staged by the 7-point Ishak 
(IS) fibrosis stage26, IS0 to IS6 (the latter representing the most severe fibrosis/cirrhosis) comparing no fibrosis 
(F0; n = 52), mild (IS1–2; n = 60) versus severe (IS5–6; n = 19) fibrosis (Supplementary Figure 10).
In the experimental cohort, AUROC distinguished performance of individual experimental biomarkers 
(Table 2). These data identified OPN, VIM, GPNMB and SPARC with the best diagnostic performance in dis-
criminating between non-cirrhotic (F0-F3) and cirrhosis (F4) with AUROCs of OPN 0.78 [CI 0.62, 0.94], VIM 
0.71 [CI 0.54, 0.87], GPNMB 0.73 [CI 0.56, 0.91] and SPARC 0.70 [CI 0.501, 0.90] (Table 2). In comparison to 
OPN and VIM that had consistent performance across different stages of fibrosis (though both show superiority 
at earlier fibrosis stages), GPNMB had diagnostic ability in latter stages of fibrosis (AUROC of >0.7). SPARC 
AUROC values were inferior to both OPN and VIM throughout the range of fibrosis. FN1 performed poorly, 
values peaked at F1 fibrosis and then returned to near baseline levels as fibrosis progressed (Fig. 5). This would 
suggest an unfavorable potential as a biomarker. However, the discriminatory ability of FN1 level to predict F1 
fibrosis is high (AUROC 0.81 [CI 0.67–0.94]), and could potentially make FN1 serum concentration useful in a 
biomarker panel.
Figure 4. Localization and quantification of SOX9-regulated proteins in fibrotic liver following Sox9-loss 
in mice with BDL-induced fibrosis. (A) Immunohistochemistry for VIM, OPN, SPARC, GPNMB and FN1 
(brown) counterstained with toludine blue. Images shown for control (Sox9fl/fl; RosaCreER−/−) and Sox9-
null (Sox9fl/fl; RosaCreER+/−) livers following CCl4 induced fibrosis. Scale bar 100 μm. (B) Quantification of 
surface area covered by individual protein staining in control (Sox9fl/fl; RosaCreER−/−) and Sox9-null (Sox9fl/
fl; RosaCreER+/−) livers in (A). All experiments are n = 5. Data are shown as means ± s.e.m. ***p < 0.001.
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As comparison of SOX9 target proteins performance, we compared all targets against previously validated 
biomarkers of fibrosis in the same samples. Specifically, hyaluronic acid (HA), Procollagen 3 N-peptide (P3NP), 
TIMP1, AST-to-Platelet Ratio Index (APRI) and the combined ELF panel were assayed and compared. All vali-
dated biomarkers/APRI values were taken at time of serum collection using unfrozen sample, in contrast to the 
experimental markers which were assessed in serum after going through a freeze-thaw cycle. Direct comparison 
of the AUROC values for each marker identified OPN and VIM as superior to APRI across all stages of fibrosis 
(Table 2). OPN and VIM also exhibited higher diagnostic performance at distinguishing earlier stages of fibrosis 
(controls and F0 fibrosis) compared to HA and P3NP, with TIMP1. However, HA, P3NP, TIMP and the combined 
ELF panel were superior in predicting F4/cirrhosis (Table 2).
Discussion
We have previously described a critical role for SOX9 in the mechanisms underlying liver fibrosis12–16. Moreover, 
in biopsy samples from patients with chronic liver disease we have established SOX9 as a predictive marker of 
progression toward cirrhosis12. In this study, we applied our knowledge of SOX9 in matrix regulation to iden-
tify and profile a panel of downstream targets in serum samples from patients with varying stages of chronic 
liver disease. Our transcriptomic analysis of Sox9 depleted HSCs revealed the extent of its role in regulating 
ECM components associated with fibrosis. Combined with our own data in liver fibrosis and studies in other 
organs12–14,16,25,27–29, we were able to further scrutinize these data to identify a cohort of highly expressed ECM 
Figure 5. Localization and quantification of SOX9-regulated proteins in fibrotic liver following Sox9-loss 
in mice with CCl4 induced fibrosis. (A) Immunohistochemistry for VIM, OPN, SPARC, GPNMB and FN1 
(brown) counterstained with toludine blue. Images shown for control (Sox9fl/fl; RosaCreER−/−) and Sox9-
null (Sox9fl/fl; RosaCreER+/−) livers following BDL induced fibrosis. Scale bar 100 μm. (B) Quantification of 
surface area covered by individual protein staining in control (Sox9fl/fl; RosaCreER−/−) and Sox9-null (Sox9fl/
fl; RosaCreER+/−) livers in (A). All experiments are n = 5. Data are shown as means ± s.e.m. *p < 0.05.
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proteins amenable to assay in patient serum samples, including OPN, VIM, SPARC, GPNMB and FN1. All targets 
were localized and highly expressed in activated HSCs from rodent and human. Four of the five targets had SOX9 
binding sites in their promoter region with increased enrichment for SOX9, whereas VIM demonstrated com-
parative changes with Sox9 knockdown suggesting indirect regulation by SOX9. In vivo, all targets were reduced 
following Sox9 deletion in mouse models of fibrosis and localized to fibrotic regions in biopsy tissue from patients 
with severe fibrosis, commensurate with increased SOX9 levels.
Although liver biopsy remains the gold-standard to assess fibrosis in the case of diagnostic uncertainty, several 
non-invasive diagnostic tools now in clinical practice are based on mechanisms underlying the disease process. 
Figure 6. Localization of SOX9-regulated proteins in fibrotic liver from human. Immunohistochemistry for 
VIM, OPN, SPARC, GPNMB and FN1 (brown) counterstained with toludine blue. Images shown for advanced 
fibrotic/cirrhotic human liver secondary to CHC infection. Scale bar 100 μm.
Figure 7. SOX9-regulated proteins are present and increased in serum from patients with liver fibrosis. (A–E) 
Serum concentration of SOX9-regulated targets quantified by ELISA and grouped by stage of fibrosis (Metavir). 
Data are shown as means ± s.e.m.
AUROC: Experimental cohort (n = 50)
Experimental biomarkers Previously validated biomarkers & biomarker panels
Fibrosis Stage OPN VIM SPARC GPNMB FN1 APRI HA P3NP TIMP1 ELF
C vs 0–4 0.797 0.876 0.834 0.457 0.597 0.313 0.348 0.256 0.111 0.276
C, 0 vs 1–4 0.802 0.788 0.779 0.531 0.684 0.687 0.652 0.744 0.889 0.724
C, 0, 1 vs 2–4 0.752 0.725 0.714 0.708 0.44 0.695 0.675 0.78 0.768 0.729
C, 0–2 vs 3, 4 0.772 0.707 0.68 0.7 0.461 0.661 0.758 0.929 0.778 0.831
C, 0–3 vs 4 0.781 0.705 0.69 0.716 0.429 0.543 0.897 0.947 0.851 0.958
Table 2. AUROC analysis.
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For example, physical approaches measuring liver stiffness, such as transient elastography (TE), take advantage 
of altered organ biomechanics in response to scarring; whereas many serum biomarker panels rely on detection 
of known ECM components indicative of the disease process9,30,31. Despite their widespread use to distinguish 
early/no fibrosis from cirrhosis, classifying patients with intermediate stages of fibrosis has proved challenging. 
Combined with our own insight into the role of SOX9 in fibrosis, we tested the SOX9-regulated ECM proteins 
as novel serum markers in a well phenotyped cohort of patients with variable fibrosis. Our data indicted two 
SOX9-regulated ECM proteins, OPN and VIM have potential as biomarkers of liver fibrosis severity; interest-
ingly, the data, for instance on AUROCs, were comparable to those from previous studies scrutinising other 
validated individual biomarkers and panels (reviewed in8). Supporting OPN and VIM as dynamic biomarkers, 
the distribution of both factors became significantly reduced in regions of scarring in mouse models of fibrosis 
resolution32,33. Conversely, elevations of OPN have been implicated in the progression of multiple chronic liver 
diseases, associated with fibrosis, including non-alcoholic steatohepatitis, alcoholic liver disease, and infection 
with either HCV or HBV20,21,34,35.
Despite FN1 performing poorly as a biomarker for progressive fibrosis, our data in the experimental cohort 
complemented previous work highlighting its potential to predict early fibrosis36. Consistent with these findings, 
fibronectin isoforms are thought to precede α-SMA expression and be involved in myofibroblast activation by 
profibrotic TGF-β37,38. Similar results were seen between the SOX9-regulated ECM proteins and three established 
clinical biomarkers (including APRI). Although TIMP1, HA and P3NP were better at identifying cirrhosis; OPN 
and VIM demonstrated superiority at earlier stages of fibrosis. This proof of concept diagnostic study provides 
encouragement for these biomarkers to be tested in larger phase 3 diagnostic studies. Importantly, a combined 
panel of SOX9 regulated ECM proteins may show superior performance for identifying earlier stages of fibrosis.
Overall, these data further support a critical role for SOX9 in the mechanisms underlying fibrosis and indicate 
the value of investigating SOX9-regulated pathways as serum biomarkers or as potential targets to reduce fibro-
sis and its progression to cirrhosis and HCC. Significantly, in our previous study, the utility of SOX9 detection 
in biopsy samples to detect severity and predict disease progression outperformed all other fibrosis risk fac-
tors12. Collectively these current and previous data highlight a potential clinical use for SOX9 and its downstream 
secreted targets as a measure to stratify patients with liver fibrosis alongside existing or emerging measures (e.g. 
cirrhosis risk score or liquid biomarkers)39–42.
Materials and Methods
Human liver tissue and serum. Liver biopsies tissue used in this study has been described previously12. 
Briefly, paired biopsy samples were obtained with informed consent and ethical approval from the Trent Cohort 
Study of Hepatitis C Virus (HCV) antibody‐positive patients from across the former UK Trent Health Region43,44 
following selection and data collection criteria as previously described43–45. Patients who were receiving therapy 
or infected with human immunodeficiency virus were excluded. Liver biopsies were assessed blindly by an expert 
liver histopathologist based on the 7-point Ishak fibrosis stage, IS0 to IS6; the latter representing the most severe 
fibrosis/cirrhosis26. We identified a cohort of 152 biopsies classified as mild fibrosis (IS0–1; n = 100) intermediate 
(IS2–3; n = 30) or severe disease (IS4–6; n = 22)12. From the same Trent HCV Cohort Study, we identified serum 
samples amenable to assay as a validation cohort. This consisted of 131 serum samples classified as IS0 (no fibro-
sis; n = 52), IS1–2 (mild fibrosis; n = 60) and IS5–6 (severe fibrosis/cirrhosis; n = 19).
As proof of concept of diagnostic performance we tested serum samples in an independent, external cohort 
of patients with chronic HCV (treatment naïve) and healthy controls (LREC no. 04/Q1701/58). All subjects were 
asked to follow dietary restrictions and avoid medicinal products for seven days prior to blood sampling and 
collection occurred between 9 am and 11am. All patients with HCV underwent a liver biopsy which was assessed 
by an expert liver histopathologist using the METAVIR scoring system. All biopsies were greater than 15 mm in 
length and contained more than six portal tracts. All research was performed in accordance with relevant guide-
lines and regulations.
Animal models of liver fibrosis and treatments. All animal research was performed in accordance 
with relevant guidelines and regulations, as described previously12,23. Mice were housed and maintained, and 
animal experiments carried out, with approval from the University of Manchester Ethical Review Committee in 
accordance with UK Government Home Office regulations and its approval (licence P7FDDE62C). Mice were 
on a C57BL/6 J background in housing with a 12-hour light dark cycle and food and water available ad libitum. 
RosaCreER mice12,46 were sourced from Jackson Laboratories. Sox9fl/fl mice were a kind gift from Professor Gerd 
Scherer12,47. To achieve inducible global Sox9 deletion, Sox9fl/fl mice were crossed with RosaCreER mice to gen-
erate RosaCreER:Sox9fl/fl animals. Genotyping, fibrosis induction and gene inactivation by tamoxifen for animals 
used in this study has been published12. Briefly, tamoxifen (Sigma, UK) was injected i.p. to activate CreER activity 
and induce Sox9 deletion in ROSACreER:Sox9fl/fl animals. ROSACreER+/− and ROSACreER−/− animals were 
injected with tamoxifen to control for any unexpected effects. 8 week carbon tetrachloride injections (CCl4) and 
two week bile duct ligation (BDL) were used to induced fibrosis in mice. Tissue and serum samples were collected 
at the end of the procedure for analysis.
For both CCl4 and BDL models of fibrosis in RosaCreER:Sox9fl/fl animals, there were four experimental groups. 
CCl4: RosaCreER−/−:Sox9fl/fl Olive Oil (n = 6); RosaCreER+/−:Sox9fl/fl Olive Oil (n = 6), RosaCreER−/−:Sox9fl/fl  
CCl4 (n = 5), and RosaCreER+/−:Sox9fl/fl CCl4 (n = 8). BDL: RosaCreER−/−:Sox9fl/fl Control (n = 5); 
RosaCreER+/−:Sox9fl/fl Control (n = 5), RosaCreER−/−:Sox9fl/fl BDL (n = 7), and RosaCreER+/−:Sox9fl/fl BDL 
(n = 5)12.
Histology, immunohistochemistry and immunocytochemistry. Tissue samples were fixed in 4% par-
aformaldehyde (PFA) and processed for histology or immunohistochemistry (IHC) as described previously12,23. 
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HSCs grown on chamber slides were also fixed in 4% PFA, then stored in PBS at 4 °C as for previous work13,16. For 
IHC in tissue, 10 mM sodium citrate (pH 6) was used for antigen retrieval, except for Osteopontin IHC which 
required pepsin (Sigma, UK). Antibodies used are listed in Supplementary Table 1. Histological collagen staining 
was carried out using picro-sirius red (PSR)12,23. All histological quantification and analysis was carried out blind 
from scanned slide images following histology as previously described12.
Primary cell culture, Quantitative PCR, Western Blotting and microarray. Primary rat and human 
hepatic stellate cells (rHSCs) were isolated and RNA and protein prepared as described previously13,16. Gene 
silencing for SOX9 was carried out in culture activated HSCs using short interfering RNA (siRNA) as previously 
indicated. qPCR used intron spanning primers wherever possible (Supplementary Table 2). Western blotting 
was done following standard protocols13,16. Protein bands were detected with primary and secondary antibodies 
listed in Supplementary Table 1. For microarray, sample preparation and analysis are detailed in supplementary 
methods23.
Elisa. Two variations of the ELISA protocol were used due to the availability and applicability of antibodies. 
Sandwich ELISA, whereby a coating antibody was initially used to capture the antigen prior to a detecting anti-
body being used to detect the relative concentration by comparing to the optical density at 450 nm of known 
standards. Where suitable capture antibodies were not available, direct ELISA was utilized and the serum sample 
was coated directly onto the plastic wells and a detecting antibody used to assay. A dilution series of known con-
centration recombinant human proteins (R&D systems) were used as standards. Accuracy of ELISAs was meas-
ured with coefficients of variation for each marker assayed and a sample was discounted if variation was >10% 
between replicates. Antibodies used are shown in Supplementary Table 1.
Chromatin Immunopreciptation. Conserved SOX9 binding sites were identified using ECR browser 
(http://ecrbrowser.dcode.org) and the MUltiple sequence Local AligNment and conservation visualization 
tool (MULAN: https://mulan.dcode.org/). Chromatin immunoprecipitation (ChIP) assays were performed as 
described previously16. Following chromatin isolation and immunoprecipitation with a SOX9 antibody (sc-20095, 
H-90, Santa Cruz), protein-DNA complexes were eluted, crosslinks reversed and protein degraded prior to DNA 
purification and PCR (Supplementary Table 1).
Statistical Analysis. Data was analysed using the SPSS 19 (IBM, USA) software package in multiple samples 
after a minimum of 3 determinations. Where appropriate, data was expressed as mean ± standard error of the 
mean (SEM). In samples with 2 groups, comparison was made using an un-paired t-test, assuming unequal var-
iance. For ELISA, assay consistency and accuracy was assessed using the average coefficient of variation (CoV). 
Serum markers’ ability to discriminate between stages of fibrosis was achieved by area under the receiver operator 
curve (AUROC) analysis with 95% confidence intervals stated.
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